Overview
- The FDA published staff briefing documents on June 29–30 that concluded the seven nominated peptides do not have sufficient human trials and cannot be deemed safe for routine compounding.
- The substances under review include BPC-157, KPV, TB-500, MOTS‑c, emideltide, semax and epitalon, which nominees proposed for uses such as wound healing, obesity, insomnia and opioid withdrawal.
- Reviewers cited specific faults: inconsistent naming and characterization, incomplete impurity and sterility testing, and an unresolved risk of immune reactions when peptides are injected.
- The agency appointed a revamped Pharmacy Compounding Advisory Committee roster that includes multiple clinicians, pharmacists and clinic operators with financial or practice ties to peptide providers; that panel will meet July 23–24 to make nonbinding recommendations.
- If the committee departs from staff findings, the decision could widen regulated compounding access or preserve restrictions and enforcement that aim to limit a large online gray market for unapproved peptide products.